Ziv-aflibercept is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Uveal Melanoma. According to GlobalData, Phase II drugs for Uveal Melanoma have a 20% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ziv-aflibercept’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ziv-aflibercept (Zaltrap / Aflitiv / Lidaveg / Zaltrapziv / Zalzen) is a recombinant fusion protein consisting of Vascular Endothelial Growth Factor (VEGF)-binding portions from the extracellular domains of human VEGF Receptors 1 and 2 fused to the Fc portion of the human IgG1. Zaltrap in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for patients with metastatic colorectal cancer.
Ziv-aflibercept is under development for the treatment of uveal melanoma. It was also under development for rectal cancer, ovarian cancer, ascites, non-small-cell-lung adenocarcinoma, metastatic pancreatic cancer, metastatic colorectal cancer, B-cell non-Hodgkin lymphoma and metastatic androgen-independent prostate cancer and non-proliferative diabetic retinopathy (NPDR). It is administered through the intravitreal route.
Regeneron Pharmaceuticals overview
Regeneron Pharmaceuticals (Regeneron) is engaged in discovering, developing, manufacturing, and marketing medicines for the treatment of serious medical conditions. Its products are focused on helping patients suffering from cancer, allergic and inflammatory diseases, eye diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, hematologic conditions, pain, and rare diseases. It develops products using its Trap and VelociSuite technology platforms, which include VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, and other related technologies. The company operates manufacturing facilities in Rensselaer, New York, and Limerick, Ireland. It also collaborates with strategic partners to develop, manufacture, and commercialize its products. It sells its products to specialty pharmacies and distributors. The company operates in the US, the Netherlands, Bermuda, Ireland, Spain, India, Japan, and the UK. Regeneron is headquartered in Tarrytown, New York, the US.
For a complete picture of Ziv-aflibercept’s drug-specific PTSR and LoA scores, buy the report here.